Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Heise MA"'
Autor:
Kahn, SE, Zinman, B, Lachin, JM, Haffner, SM, Herman, WH, Holman, RR, Kravitz, BG, Yu, D, Heise, MA, Aftring, RP, Viberti, G
OBJECTIVE: The purpose of this study was to examine possible factors associated with the increased risk of fractures observed with rosiglitazone in A Diabetes Outcome Progression Trial (ADOPT). RESEARCH DESIGN AND METHODS: Data from the 1,840 women a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::cf43abbad6caf259c8dfcb1a2ca01587
https://ora.ox.ac.uk/objects/uuid:6ed8b84e-8b36-4d9b-a3a0-3987d60a2602
https://ora.ox.ac.uk/objects/uuid:6ed8b84e-8b36-4d9b-a3a0-3987d60a2602
Autor:
Bonnie Louridas, Alexander R. Cobitz, Stephen O. McMorn, Gary G. Koch, Andrew Zambanini, Margaret Sowell, Marc J. Semigran, Heise Ma
Publikováno v:
Pharmacoepidemiology and Drug Safety. 17:769-781
Retrospectively investigate potential associations between rosiglitazone and congestive heart failure (CHF) and, separately, events of myocardial ischemia.Data from 14 237 individuals in 42 short-term, double-blind, randomized studies of rosiglitazon
Autor:
Heise Ma, Steven E. Kahn, Bernard Zinman, O'Neill Mc, John M. Lachin, Nigel P. Jones, William H. Herman, Barbara G. Kravitz, Steven M. Haffner, Rury R. Holman, Giancarlo Viberti
Publikováno v:
New England Journal of Medicine. 355:2427-2443
BACKGROUND: The efficacy of thiazolidinediones, as compared with other oral glucose-lowering medications, in maintaining long-term glycemic control in type 2 diabetes is not known. METHODS: We evaluated rosiglitazone, metformin, and glyburide as init
Autor:
Luis M. Ruilope, L E Porter, Martin I. Freed, Wayde M. Weston, Heise Ma, George L. Bakris, Stephen O. McMorn
Publikováno v:
Journal of Hypertension. 24:2047-2055
To test the hypothesis that rosiglitazone combined with metformin provides a greater reduction in microalbuminuria and blood pressure than metformin and glyburide at comparable levels of glycemic control.In a double-blind, parallel-group design 389 p
Autor:
Natalie Compton, Thomas E. Hutson, Lini Pandite, Neil Kaplowitz, Mei Chen, Sergio Bracarda, Thomas Powles, Christopher L. Carpenter, Heise Ma, Elliot Norry, Philipp Harter
Publikováno v:
Eur J Cancer
Drug-induced liver chemistry abnormalities, primarily transaminase elevations, are commonly observed in pazopanib-treated patients. This meta-analysis characterises liver chemistry abnormalities associated with pazopanib. Data of pazopanib-treated pa
Publikováno v:
Journal of Human Hypertension. 17:7-12
This study examines the effect of rosiglitazone on urinary albumin excretion (UAE) in patients with type II diabetes. Urinary albumin: creatinine ratio (ACR) was measured in a 52-week, open-label, cardiac safety study comparing rosiglitazone and glyb
Autor:
William H. Herman, Bernard Zinman, John M. Lachin, Giancarlo Viberti, Martin I. Freed, Daniel Levy, Douglas A. Greene, Steven E. Kahn, Rury R. Holman, Nigel P. Jones, Heise Ma, Steven M. Haffner, Rhona A. Berry
Publikováno v:
Diabetes Care. 25:1737-1743
OBJECTIVE—Therapies with metformin, sulfonylureas, or insulin improve glycemic control in the short term but do not prevent progressive islet β-cell failure or long-term deterioration in glycemia. Our goal was to evaluate, in patients recently dia
Autor:
Steven M. Haffner, Steven E. Kahn, Barbara G. Kravitz, Martin I. Freed, Giancarlo Viberti, John M. Lachin, O'Neill Mc, Heise Ma, William H. Herman, Rury R. Holman, Nigel P. Jones, Bernard Zinman
Publikováno v:
Diabetic medicine : a journal of the British Diabetic Association. 23(12)
Aims To examine baseline characteristics of patients recruited into ADOPT, a multinational trial comparing three oral glucose-lowering monotherapies. Methods Between April 2000 and June 2002, 4360 patients aged 30–75 years with Type 2 diabetes diag
Autor:
Julio Rosenstock, L E Porter, Martin I. Freed, M. Colleen O’Neill, Heise Ma, R. G. Dirani, Barry J. Goldstein, Barbara G. Kravitz, A. I. Vinik
Publikováno v:
Diabetes, obesitymetabolism. 8(1)
To compare the efficacy, safety and tolerability of adding rosiglitazone (RSG) vs. sulphonylurea (SU) dose escalation in older type 2 diabetes mellitus (T2DM) patients inadequately controlled on SU therapy.A total of 227 T2DM patients from 48 centres
Publikováno v:
Diabetes. 53(12)
A number of patients with type 2 diabetes are GAD antibody positive. A Diabetes Outcome Progression Trial (ADOPT) is a randomized, double-blind clinical trial in recently diagnosed drug-naïve patients with type 2 diabetes that allows for the evalua